Godzilla Blend: CJC-1295 No DAC (5mg) + Ipamorelin (5mg)

For research use only. Not for human consumption. Not a TGA-registered therapeutic good. The Godzilla Blend combines CJC-1295 No DAC and Ipamorelin — two growth hormone secretagogues studied for their complementary mechanisms of action on the GH axis. Each compound operates through independent receptor pathways, making this combination a subject of significant investigation in preclinical GH release research. Compound Profiles CJC-1295 No DAC (Modified GRF 1-29) — GHRH Analogue: A 29-amino acid analogue of growth hormone-releasing hormone. Studied for stimulation of endogenous GH release via the GHRH receptor on somatotroph cells. Produces pulsatile GH release patterns more consistent with physiological secretion. Preclinical models report increased GH and IGF-1 levels post-administration. Ipamorelin — Selective GHS-R Agonist: A pentapeptide ghrelin mimetic studied for selective stimulation of GH release without significant elevation of cortisol, prolactin, or ACTH. Preclinical research demonstrates dose-dependent GH release with a favourable selectivity profile. Combined Mechanism: CJC-1295 No DAC and Ipamorelin act on distinct receptor populations (GHRH-R and GHS-R respectively), producing synergistic GH release in co-administration studies. Contents Component Size Purity CJC-1295 No DAC 5mg 99%+ HPLC Ipamorelin 5mg 99%+ HPLC Lyophilised blend, HPLC verified. Certificate of Analysis available on request. Reconstitution Guidelines Reconstitute with bacteriostatic water. Recommended: 1-2mg/ml per peptide equivalent. Use our Peptide Reconstitution Calculator Storage Lyophilised: 2-8°C, protected from light | Reconstituted: 2-8°C, use within 28 days | Long-term: -20°C Verify Our Beligas Authorisation AU Supplement Co is an authorised Beligas reseller. Verify at beligas.org/verify-distributors. For research use only. Not for human consumption. Not a TGA-registered therapeutic good.